“Will treatment make me impotent?” It’s a question on the minds of many men as they are making decisions about prostate cancer treatment. A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles and arteries involved in sexual function to preserve potency in patients getting radiation therapy for prostate cancer.
“Nowadays, mortality after treatment for localized prostate cancer is as low as 1 percent at 10 years,” said Dr. Neil Desai, Assistant Professor of Radiation Oncology and Principal Investigator of the POTEN-C trial. “By contrast, as many as half of all patients being treated for prostate cancer will experience some decline in sexual function. It is appropriate, therefore, that our focus has shifted to this aspect of quality of life.”
The new technique being tested involves reducing the dose of radiation on one side of the prostate, where imaging shows no cancer, in order to spare nerves and blood vessels on that side. To achieve this goal, patients in the study will be treated with a highly precise form of radiation called stereotactic ablative radiotherapy (SAbR), and a spacer gel (SpaceOAR) will be placed between the rectum and prostate, which may help reduce the radiation dose to nerve bundles involved in sexual function. Half the patients in the study will be randomly assigned to the new radiation technique with reduced dosage on one side and the other half will receive standard SAbR.
Kevin Stanfield of Mount Vernon, Texas, said he became a detective, scoping out all the options – watch-and-wait surveillance, surgery, radiation – when he learned he had prostate cancer. He chose radiation and participation in the POTEN-C trial.
“The potency was a big deal,” said Mr. Stanfield. “It’s not that I’m some sort of Romeo or anything, but my wife is a few years younger than me. We enjoy our time together.”
Mr. Stanfield will be one of 120 patients enrolled in the study, which will include patients at up to nine major medical center sites. All patients in the study will be followed for two years. UT Southwestern will lead the clinical trial, building on its earlier work.
Dr. Robert Timmerman, Professor of Radiation Oncology and Neurological Surgery, has been at the forefront of national efforts to advance stereotactic ablative radiotherapy, or high-intensity, high-precision radiation therapy in prostate cancer. SAbR, which involves fewer radiation treatments as well as less damage to healthy tissue, has become standard treatment in many situations.
UT Southwestern took part in clinical trials proving the value of the biodegradable spacer gel SpaceOAR that is used to protect the rectum from damage during radiation treatment for prostate cancer.
The POTEN-C trial incorporates both earlier projects, culminating in what Dr. Desai hopes will be a way to reduce the burden of therapy on men and their partners.
“We’re using advances in MRI imaging to locate the disease, the SAbR technique’s precision, and now the SpaceOAR gel to plan a new approach to reducing sexual dysfunction,” he said. “We are excited to be able to combine the results from the last 10 years of research to improve the outlook for our patients who require prostate cancer treatment. We’re aiming to give men more choices, trying to preserve their potency upfront. If this ends up being a positive trial, it’s a pretty big deal for our field.”
The POTEN-C trial is funded by Augmenix, the maker of SpaceOAR gel. For more information about the trial, call 214-648-1836 or 214-645-8525.